J&J to buy Swiss biopharma firm Actelion for $30 billion

Markets Associated Press

  • FILE - This Thursday, Feb. 22, 2007, file photo shows the headquarters of biopharmaceutical company Actelion, in Allschwil, Switzerland. In a deal announced Thursday, Jan. 26, 2017, Johnson & Johnson is buying Swiss pharmaceutical Actelion in a $30 billion deal that will boost its treatments for life-threatening high blood pressure conditions. (Georgios Kefalas/Keystone via AP, File)

    FILE - This Thursday, Feb. 22, 2007, file photo shows the headquarters of biopharmaceutical company Actelion, in Allschwil, Switzerland. In a deal announced Thursday, Jan. 26, 2017, Johnson & Johnson is buying Swiss pharmaceutical Actelion in a $30 ... billion deal that will boost its treatments for life-threatening high blood pressure conditions. (Georgios Kefalas/Keystone via AP, File) (The Associated Press)

  • FILE - In this July 30, 2013, file photo, large banners hang in an atrium at the headquarters of Johnson & Johnson in New Brunswick, N.J. In a deal announced Thursday, Jan. 26, 2017, Johnson & Johnson is buying Swiss pharmaceutical Actelion in a $30 billion deal that will boost its treatments for life-threatening high blood pressure conditions. (AP Photo/Mel Evans, File)

    FILE - In this July 30, 2013, file photo, large banners hang in an atrium at the headquarters of Johnson & Johnson in New Brunswick, N.J. In a deal announced Thursday, Jan. 26, 2017, Johnson & Johnson is buying Swiss pharmaceutical Actelion in a $30 ... billion deal that will boost its treatments for life-threatening high blood pressure conditions. (AP Photo/Mel Evans, File) (The Associated Press)

  • FILE - This Friday, Oct. 10, 2008, file photo illustration shows Johnson & Johnson products, in Philadelphia. In a deal announced Thursday, Jan. 26, 2017, Johnson & Johnson is buying Swiss pharmaceutical Actelion in a $30 billion deal that will boost its treatments for life-threatening high blood pressure conditions. (AP Photo/Matt Rourke, File)

    FILE - This Friday, Oct. 10, 2008, file photo illustration shows Johnson & Johnson products, in Philadelphia. In a deal announced Thursday, Jan. 26, 2017, Johnson & Johnson is buying Swiss pharmaceutical Actelion in a $30 billion deal that will boost ... its treatments for life-threatening high blood pressure conditions. (AP Photo/Matt Rourke, File) (The Associated Press)

Johnson & Johnson is buying Swiss biopharmaceutical company Actelion Ltd. for about $30 billion, handing the U.S.-based health care products giant a chance to boost its presence in innovative biotech treatments.

Continue Reading Below

Under the deal announced Thursday, the New Jersey-based maker of Band-Aids and prescription drugs says it will boost its portfolio of medicines and late-stage products in a complementary fit with Actelion's area of expertise.

Actelion's research and development unit is to be spun off into a Swiss-based stand-alone company.

Shares of Actelion jumped around 20 percent to 46.20 Swiss francs Zurich trading following the announcement.

The deal, approved unanimously by both companies' boards, is to be completed in the second quarter, pending regulatory approvals.

J&J says it expects the deal to immediately boost revenues and earnings per share.